Imagine a fast-track health check that can stop a virus from passing from mother to baby during breastfeeding. Instead of waiting days for lab results, doctors use portable machines to get answers on the spot and start treatment immediately. It's like having a high-tech clinic in a suitcase to protect infants in remote areas.
High rates of pediatric HIV transmission during breastfeeding due to slow diagnostic turnaround times. Current systems fail to provide immediate treatment to at-risk infants in rural settings.
A hybrid effectiveness/implementation study protocol and a mobile testing network using POC machines and Xpert platforms.
If you are a device manufacturer dealing with low adoption of diagnostic tools in rural areas — this project developed a mobile testing strategy that uses POC machines to reach 2000 children. This proves the demand and operational viability for portable viral load and EID platforms in challenging environments.
If you are a drug producer dealing with inefficient distribution of infant prophylaxis — this project tested a strategy using single-drug lamivudine for at-risk infants. This provides evidence on the effectiveness of specific drug regimens to reach zero transmission rates.
If you are a service provider dealing with the gap between clinical trials and real-world use — this project used the RE-AIM model to identify barriers to uptake. This provides a blueprint for scaling health interventions across 40 clusters in urban and rural settings.
Based on available project data, the specific price per patient is not listed, but the project includes a dedicated health economic component to assess cost-effectiveness.
The project is testing scalability by using 40 clusters (maternal and child health centres) and mobile teams to reach 2000 children in two Zambian provinces.
Based on available project data, no specific patents are mentioned; the focus is on the implementation of existing health technologies like POC machines and lamivudine.
The project experienced delays in regulatory approvals, with the final authorization granted on January 09, 2025.
The project runs from July 1, 2023, to June 30, 2027, with the clinical trial expected to start in early March 2025.
The consortium is purely academic and research-driven, consisting of 5 partners from 4 countries (FR, NO, UG, ZM). With 3 universities and 1 research organization, there is a 0% industry ratio, indicating that the project is currently in the evidence-generation phase rather than the commercialization phase.
Contact the Universite de Montpellier regarding the RE-AIM implementation results.
Contact us to identify partners for scaling these POC diagnostic protocols.
